PharmaSyntez, the leading technology enterprise in Russia, focused on the production of state-of-the-art pharmaceuticals, is on the brink of launching a trio of groundbreaking recombinant human insulin products, namely Gensulin M30, Gensulin H, and Gensulin P. These distinct and advanced medical compounds will be produced in the ultra-modern Pharmasyntez-Nord plant. The plant has the ability to produce over 5 million units of insulin every year. The different types of presentation include vials, disposable syringe pens, and cartridges designed for reusable syringe pens.
In the upcoming fall, PharmaSyntez is set to commence the production of insulin analogs like insulin glargine and insulin lispro. These groundbreaking products are the result of a collaborative effort between PharmaSyntez and Gan & Lee Pharmaceuticals (China). In this way, the company will be able to effectively address the crucial goal of supplying Russian patients with top-notch Russian alternatives to indispensable medications.
Pharmasyntez-Nord, a division of the Pharmasyntez corporate group, is committed to developing cutting-edge and highly efficient medications to treat cancer, autoimmune disorders, and endocrine system disorders. They achieve this through the utilization of a state-of-the-art research and manufacturing facility.
Pharmasyntez-Nord currently produces a remarkable 45 diverse varieties of oncology medications, of which an impressive 99% are listed as vital and essential drugs by the Russian Ministry of Health.
